Creating First-in-Class Treatments to Deliver
Better Patient Outcomes

Imagine Pharma is committed to expanding and building its pipeline of programs across each of its platforms. These programs address multiple disease states and unmet needs in large underserved markets.

Descriptions of our existing programs by platform can be found below.

Oral Delivery Platform

PT-1 EPO

The first of its kind, PT-1 EPO is the oral form of Epogen, a well-established drug for the treatment of anemia in patients with renal failure, undergoing chemotherapy and other causes.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

PT-2 Octreotide

Oral form of octreotide for the treatment of carcinoid tumors and debilitating symptoms of carcinoid syndrome

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

PT-3 GLP-1 Agonist

Oral form of GLP-1 agonist used for the treatment of type 2 diabetes

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

Therapeutics Platform

Top-1 Skin Graft (Donor)

Top-1 therapy can accelerate the re-epithelialization and healing of partial thickness skin donor sites which can reduce pain and time to healing.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

Top-2 Diabetic Wound

Top-2 can accelerate the healing of diabetic wounds by expediting re-epithelialization, skin regeneration, and collagen deposition.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

Top-3 Burns (2nd Degree)

Top-3 therapy can accelerate the re-epithelialization and healing of second degree burn sites which can reduce pain and time to healing.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

Regenerative Medicine Platform

AIPCs

Limitless numbers of insulin-producing islet cells can be generated from a single pancreas by Imagine Pharma’s innovative growth factors and technique. These islet cells can be transplanted (IV) into type 1 diabetic patients as a cure for their disease.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1

T1 Diabetes Autologous Transplant

Imagine Pharma can isolate and propagate insulin producing islet cells from biopsies of type 1 diabetic pancreases. This revolution in islet isolation and propagation allows the generation and propagation of Beta cells from T1D patients and the autologous islet transplantation to cure type 1 diabetes.

DiscoveryPre-ClinicalPhase 1
Discovery
Pre-Clinical
Phase 1
Key
2021-2022
2022-2023

RESEARCH & DEVELOPMENT ENGINE

Powering New Discovery

The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.

We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.

R & D EngineDiscoveryPre-ClinicalPhase 1
2nd Generation Oral Delivery System
Discovery
Pre-Clinical
Phase 1
Additional Oral Biologics
Discovery
Pre-Clinical
Phase 1
Comprehensive Lung Healing Initiative
Discovery
Pre-Clinical
Phase 1
Comprehensive Bowel Initiative
Discovery
Pre-Clinical
Phase 1
Personalized Blood
Vessel
Discovery
Pre-Clinical
Phase 1